Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mepolizumab - GlaxoSmithKline

Drug Profile

Mepolizumab - GlaxoSmithKline

Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University; National Institute of Allergy and Infectious Diseases
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Registered Churg-Strauss syndrome
  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Hypereosinophilic syndrome; Nasal polyps
  • Phase II Atopic dermatitis; Eosinophilic oesophagitis

Most Recent Events

  • 13 Nov 2019 GlaxoSmithKline announces intention to submit regulatory applications, in 2020
  • 13 Nov 2019 Mepolizumab receives Fast Track designation for Hypereosinophilic syndrome [SC,Injection] in USA, prior to November 2019
  • 13 Nov 2019 Efficacy data from a phase III trial in Hypereosinophilic syndrome released by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top